Issue link: https://www.e-digitaleditions.com/i/1515319
This section provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. 18 February 2024 Inhalation ISSUE FOCUS Product Development/Contract Testing This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No product endorsement or preference is intended. MDI canister coating Big changes are coming, especially related to future per- and polyfluoroalkyl substances (PFAS) bans. Biomerics can help you stay out in front of them with our new, patent pending, 100% PFAS-free metered dose inhaler (MDI) canister coating. So far, pharma- ceutical test results show equivalency to current PFAS coatings. Please reach out to us and let us know how we can support your MDI projects. Biomerics US: +1 540 246-1930 rchurchill@biomerics.com www.biomerics.com Qualitative nasal deposition studies Proveris Laboratories offers nasal deposition studies using a proprietary human-idealized nasal cast model. Nasal casts provide cost-effective and rapid means for evaluating nasal deposition in a human-realistic man- ner. Studies follow the Proveris by Design™ process to measure the effects of human-usage parameters (insertion angle, insertion depth and patient- specific breathing) on regional deposition. Performing these studies during early development reduces the risk of late-stage failures by creating a product that can be used correctly by the intended patient in clin- ical studies and beyond. Learn more: https://bit. ly/3TTqWnL. Proveris Laboratories US: +1 508 460-8822 contactus@proveris.com www.proveris.com Reformulating pMDIs with greener propellants Currently marketed pressurized metered dose inhaler (pMDI) products are under scrutiny due to the high global warming potential of the main propellant con- stituent of their formulations. In light of the Kigali Amendment to the Montreal Protocol and increasing focus on environmental, social, and corporate gover- nance (ESG) themes in general, many pharmaceu- tical companies are looking at re-formulating these products with newer, greener propellant technologies. Intertek uses over 30 years of experience with pMDIs to provide support for the formulation and analytical testing required for these technical programs. Intertek Pharmaceutical Services UK: +44 1763 261648 bd.melbourn@intertek.com www.intertek.com